{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:25:32Z","timestamp":1780392332355,"version":"3.54.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018623","name":"Quanzhou City Science and Technology Program","doi-asserted-by":"publisher","award":["2022NS066"],"award-info":[{"award-number":["2022NS066"]}],"id":[{"id":"10.13039\/501100018623","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Metabolic dysfunction-associated steatotic liver disease, a prevalent chronic liver condition, can cause severe complications like hepatitis, cirrhosis, and hepatocellular carcinoma. In recent years, glucagon-like peptide-1 receptor agonists (GLP - 1RA) have shown unique therapeutic advantages and may become a preferred treatment for it. This meta-analysis aims to systematically examine GLP-1RA associated adverse events, providing a basis for guiding patient clinical management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a search for randomized controlled trials (RCTs) investigating the therapeutic effects of GLP-1RA in the treatment of metabolic dysfunction-associated steatotic liver disease across four databases: PubMed, Embase, Web of Science, and Cochrane Library. The search period extended from the inception of each database until December 2023. Information pertaining to various adverse events was collected as outcome measures. Statistical analysis of the results and assessment of bias risk were conducted utilizing Review Manager (version 5.4.1) software.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>An analysis of 10 studies encompassing 960 participants revealed a significantly higher overall incidence of adverse events in the GLP-1RA group compared to the control group (OR: 2.40 [1.10, 5.26], <jats:italic>P<\/jats:italic> = 0.03). Subgroup analysis based on treatment duration demonstrated a higher rate of adverse events in the GLP-1RA group during follow-ups of less than 30 weeks (<jats:italic>P<\/jats:italic> = 0.0005, OR: 3.58 [1.75, 7.32]), but no statistical difference was observed between the two groups in follow-ups exceeding 30 weeks. There was no statistically significant difference between the two groups in adverse events leading to discontinuation (<jats:italic>P<\/jats:italic> = 0.29, OR: 1.47 [0.72, 2.98]). However, a notable difference was observed in gastrointestinal adverse events (<jats:italic>P<\/jats:italic> &amp;lt; 0.00001, OR: 4.83 [3.36, 6.95]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>GLP-1RA exhibits an overall higher incidence of adverse events in the treatment of metabolic dysfunction-associated steatotic liver disease, particularly in the gastrointestinal domain. Short-term use of GLP-1RA may be associated with a greater occurrence of adverse events, underscoring the importance of educating patients on preventive measures and establishing tolerance. However, there was no statistically significant difference between the two groups in severe adverse events and adverse events leading to discontinuation, confirming the safety profile of GLP-1RA application.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1509947","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T06:38:23Z","timestamp":1740033503000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Gastrointestinal adverse events associated with GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Xiaoyan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaohui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoliang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: A multisystem disease.","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nrneph.2017.16","article-title":"Non-alcoholic fatty liver disease: An emerging driving force in chronic kidney disease.","volume":"13","author":"Targher","year":"2017","journal-title":"Nat Rev Nephrol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.","volume":"66","author":"Adams","year":"2017","journal-title":"Gut."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","article-title":"Epidemiological features of NAFLD from 1999 to 2018 in China.","volume":"71","author":"Zhou","year":"2020","journal-title":"Hepatology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: Clinical associations, pathophysiological mechanisms and pharmacological implications.","volume":"69","author":"Targher","year":"2020","journal-title":"Gut."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: Current evidence and future perspectives.","volume":"24","author":"Nevola","year":"2023","journal-title":"Int J Mol Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH.","volume":"53","author":"Sumida","year":"2018","journal-title":"J Gastroenterol."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1087260","article-title":"Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD).","volume":"13","author":"Rong","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/hep.32235","article-title":"A GLP-1\/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome.","volume":"75","author":"Kim","year":"2022","journal-title":"Hepatology."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.721198","article-title":"GLP-1 and underlying beneficial actions in Alzheimer\u2019s disease, hypertension, and NASH.","volume":"12","author":"Li","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s11095-022-03302-1","article-title":"Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: A narrative review.","volume":"39","author":"Mahapatra","year":"2022","journal-title":"Pharm Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss.","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: A systematic review and meta-analysis.","volume":"65","author":"Karagiannis","year":"2022","journal-title":"Diabetologia."},{"key":"B14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.hjc.2018.11.008","article-title":"GLP-1 receptor agonists and cardiovascular outcome trials: An update.","volume":"60","author":"Andrikou","year":"2019","journal-title":"Hellenic J Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations.","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature.","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ."},{"key":"B18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u22c54 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: A randomised, placebo-controlled phase 2 trial.","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis.","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.","volume":"79","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study.","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/liv.14065","article-title":"Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease.","volume":"39","author":"Khoo","year":"2019","journal-title":"Liver Int."},{"key":"B25","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.clinre.2020.01.007","article-title":"Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease.","volume":"44","author":"Zhang","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108487","article-title":"Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.","volume":"170","author":"Guo","year":"2020","journal-title":"Diabetes Res Clin Pract."},{"key":"B27","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/dom.15359","article-title":"Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open-label, controlled trial.","volume":"26","author":"Fan","year":"2024","journal-title":"Diabetes Obes Metab."},{"key":"B28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: Cardiovascular benefits and mechanisms of action.","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1056\/NEJMoa1903822","article-title":"Liraglutide in children and adolescents with Type 2 diabetes.","volume":"381","author":"Tamborlane","year":"2019","journal-title":"N Engl J Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1517\/14740338.2015.987122","article-title":"Potential side effects to GLP-1 agonists: Understanding their safety and tolerability.","volume":"14","author":"Consoli","year":"2015","journal-title":"Expert Opin Drug Saf."},{"key":"B32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial.","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s12325-022-02394-w","article-title":"GLP-1 agonists for weight loss: Pharmacology and clinical implications.","volume":"40","author":"Moore","year":"2023","journal-title":"Adv Ther."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061807","article-title":"Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight\/obese patients with or without diabetes mellitus: A systematic review and network meta-analysis.","volume":"13","author":"Ma","year":"2023","journal-title":"BMJ Open."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes.","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials.","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/279530","article-title":"Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function.","volume":"2011","author":"Marathe","year":"2011","journal-title":"Exp Diabetes Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40279-018-01034-0","article-title":"Exit gluten-free and enter low FODMAPs: A novel dietary strategy to reduce gastrointestinal symptoms in athletes.","volume":"49","author":"Lis","year":"2019","journal-title":"Sports Med."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/nu16162618","article-title":"Association between dietary inflammatory index and Hyperemesis gravidarum.","volume":"16","author":"Zhi","year":"2024","journal-title":"Nutrients."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/s12970-021-00458-w","article-title":"International society of sports nutrition position stand: Sodium bicarbonate and exercise performance.","volume":"18","author":"Grgic","year":"2021","journal-title":"J Int Soc Sports Nutr."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: Systematic review and network meta-analysis.","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity.","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1149328","article-title":"GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: A system review and network meta-analysis.","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1416985","article-title":"Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events.","volume":"15","author":"He","year":"2024","journal-title":"Front Pharmacol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1509947\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T06:38:26Z","timestamp":1740033506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1509947\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":44,"alternative-id":["10.3389\/fmed.2025.1509947"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1509947","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"article-number":"1509947"}}